Nippon Chemiphar Co Ltd (4539)

Currency in JPY
1,574.0
+37.0(+2.41%)
Closed·
4539 Scorecard
Full Analysis
Operates with a significant debt burden
4539 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,537.01,577.0
52 wk Range
1,410.01,675.0
Key Statistics
Bid/Ask
1,540.00 / 1,577.00
Prev. Close
1,537
Open
1,537
Day's Range
1,537-1,577
52 wk Range
1,410-1,675
Volume
4.1K
Average Volume (3m)
2.42K
1-Year Change
1.18%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4539 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Nippon Chemiphar Co Ltd Company Profile

Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development; NC-2500, a XOR inhibitor for the treatment of hyperuricemia/gout currently under phase 1 development; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain currently under phase 1 development. In addition, the company develops NC-2700, a URAT1 inhibitor for hyperuricemia, guot currently under preclinical development; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety currently under Phase 1 development; DFP-17729, a cancer microenvironment improving agent far pancreatic cancer currently under phase 2 development; and DE-P-14323, an anti-cancer agent for non-small cell lung cancer currently under phase 2 development. Further, it is involved in the development of Soleton, an analgesic and anti-inflammatory drug; and Calvan, a blocker for huntington's disease currently under phase 2 development. Additionally, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various types of creams. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was incorporated in 1950 and is headquartered in Tokyo, Japan.

Employees
855
Market
Japan

Compare 4539 to Peers and Sector

Metrics to compare
4539
Peers
Sector
Relationship
P/E Ratio
14.2x12.5x−0.5x
PEG Ratio
0.040.120.00
Price/Book
0.3x1.0x2.6x
Price / LTM Sales
0.2x1.3x3.3x
Upside (Analyst Target)
-10.0%42.8%
Fair Value Upside
Unlock17.0%6.5%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 109.48%
Dividend Yield
3.25%
Industry Median 2.49%
Annualised payout
50.00
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Jul 31, 2025
EPS / Forecast
62.92 / --
Revenue / Forecast
8.25B / --
EPS Revisions
Last 90 days

4539 Income Statement

FAQ

What Stock Exchange Does Nippon Chemiphar Trade On?

Nippon Chemiphar is listed and trades on the Tokyo Stock Exchange stock exchange.

What Is the Stock Symbol for Nippon Chemiphar?

The stock symbol for Nippon Chemiphar is "4539."

What Is the Nippon Chemiphar Market Cap?

As of today, Nippon Chemiphar market cap is 5.58B.

What Is Nippon Chemiphar's Earnings Per Share (TTM)?

The Nippon Chemiphar EPS (TTM) is 109.48.

When Is the Next Nippon Chemiphar Earnings Date?

Nippon Chemiphar will release its next earnings report on 28 Oct 2025.

From a Technical Analysis Perspective, Is 4539 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Nippon Chemiphar Stock Split?

Nippon Chemiphar has split 1 times.

How Many Employees Does Nippon Chemiphar Have?

Nippon Chemiphar has 855 employees.

What is the current trading status of Nippon Chemiphar (4539)?

As of 06 Aug 2025, Nippon Chemiphar (4539) is trading at a price of 1,574.00, with a previous close of 1,537.00. The stock has fluctuated within a day range of 1,537.00 to 1,577.00, while its 52-week range spans from 1,410.00 to 1,675.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.